vs
Orthofix Medical Inc.（OFIX）とUSA Compression Partners, LP（USAC）の財務データ比較。上の社名をクリックして会社を切り替えられます
USA Compression Partners, LPの直近四半期売上が大きい（$252.5M vs $219.9M、Orthofix Medical Inc.の約1.1倍）。USA Compression Partners, LPの純利益率が高く（11.0% vs -1.0%、差は12.0%）。USA Compression Partners, LPの前年同期比売上増加率が高い（2.7% vs 2.0%）。USA Compression Partners, LPの直近四半期フリーキャッシュフローが多い（$87.7M vs $16.8M）。過去8四半期でOrthofix Medical Inc.の売上複合成長率が高い（8.0% vs 4.9%）
オーソフィックスメディカル社は世界的な整形外科医療機器メーカーで、脊椎インプラント、整形外科用外傷治療製品、骨成長刺激療法機器、再生医療製品の開発・製造・販売を事業としています。北米、欧州、アジア太平洋を中心に整形外科医や医療機関向けに製品を提供し、筋骨格系疾患患者の治療成績向上に取り組んでいます。
USA Compression Partners, LPは米国に本拠を置く天然ガス圧縮サービスプロバイダーであり、石油・ガス業界の上流・中流・下流分野の顧客向けに、カスタム圧縮システム、保守サービス、運用支援を提供し、天然ガスの生産・加工・輸送の効率化を支えています。
OFIX vs USAC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $219.9M | $252.5M |
| 純利益 | $-2.2M | $27.8M |
| 粗利率 | 71.1% | — |
| 営業利益率 | 0.2% | 30.3% |
| 純利益率 | -1.0% | 11.0% |
| 売上前年比 | 2.0% | 2.7% |
| 純利益前年比 | 92.4% | 9.1% |
| EPS（希薄化後） | $-0.05 | — |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $219.9M | $252.5M | ||
| Q3 25 | $205.6M | $250.3M | ||
| Q2 25 | $203.1M | $250.1M | ||
| Q1 25 | $193.6M | $245.2M | ||
| Q4 24 | $215.7M | $245.9M | ||
| Q3 24 | $196.6M | $240.0M | ||
| Q2 24 | $198.6M | $235.3M | ||
| Q1 24 | $188.6M | $229.3M |
| Q4 25 | $-2.2M | $27.8M | ||
| Q3 25 | $-22.8M | $34.5M | ||
| Q2 25 | $-14.1M | $28.6M | ||
| Q1 25 | $-53.1M | $20.5M | ||
| Q4 24 | $-29.1M | $25.4M | ||
| Q3 24 | $-27.4M | $19.3M | ||
| Q2 24 | $-33.4M | $31.2M | ||
| Q1 24 | $-36.0M | $23.6M |
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
| Q4 25 | 0.2% | 30.3% | ||
| Q3 25 | -8.3% | 33.5% | ||
| Q2 25 | -7.9% | 30.6% | ||
| Q1 25 | -25.2% | 28.3% | ||
| Q4 24 | -5.3% | 30.3% | ||
| Q3 24 | -9.6% | 31.5% | ||
| Q2 24 | -12.5% | 32.9% | ||
| Q1 24 | -15.6% | 29.2% |
| Q4 25 | -1.0% | 11.0% | ||
| Q3 25 | -11.1% | 13.8% | ||
| Q2 25 | -6.9% | 11.4% | ||
| Q1 25 | -27.4% | 8.4% | ||
| Q4 24 | -13.5% | 10.3% | ||
| Q3 24 | -13.9% | 8.1% | ||
| Q2 24 | -16.8% | 13.3% | ||
| Q1 24 | -19.1% | 10.3% |
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $-0.57 | — | ||
| Q2 25 | $-0.36 | — | ||
| Q1 25 | $-1.35 | — | ||
| Q4 24 | $-0.76 | — | ||
| Q3 24 | $-0.71 | — | ||
| Q2 24 | $-0.88 | — | ||
| Q1 24 | $-0.95 | — |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $82.0M | $8.6M |
| 総負債低いほど良い | — | $2.5B |
| 株主資本純資産 | $450.0M | — |
| 総資産 | $850.6M | $2.6B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $82.0M | $8.6M | ||
| Q3 25 | $62.9M | — | ||
| Q2 25 | $65.6M | $2.0K | ||
| Q1 25 | $58.0M | $2.0K | ||
| Q4 24 | $83.2M | $14.0K | ||
| Q3 24 | $30.1M | $79.0K | ||
| Q2 24 | $26.4M | $9.0K | ||
| Q1 24 | $27.0M | $8.0K |
| Q4 25 | — | $2.5B | ||
| Q3 25 | $157.2M | $2.5B | ||
| Q2 25 | $157.0M | $2.5B | ||
| Q1 25 | $156.9M | $2.5B | ||
| Q4 24 | $157.0M | $2.5B | ||
| Q3 24 | $118.5M | $2.5B | ||
| Q2 24 | $118.0M | $2.5B | ||
| Q1 24 | $118.2M | $2.5B |
| Q4 25 | $450.0M | — | ||
| Q3 25 | $442.5M | — | ||
| Q2 25 | $458.3M | — | ||
| Q1 25 | $458.3M | — | ||
| Q4 24 | $503.1M | — | ||
| Q3 24 | $525.9M | — | ||
| Q2 24 | $546.0M | — | ||
| Q1 24 | $570.3M | — |
| Q4 25 | $850.6M | $2.6B | ||
| Q3 25 | $832.6M | $2.7B | ||
| Q2 25 | $837.2M | $2.7B | ||
| Q1 25 | $823.1M | $2.7B | ||
| Q4 24 | $893.3M | $2.7B | ||
| Q3 24 | $867.9M | $2.8B | ||
| Q2 24 | $882.0M | $2.8B | ||
| Q1 24 | $906.0M | $2.8B |
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $27.7M | $139.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $16.8M | $87.7M |
| FCFマージンFCF / 売上 | 7.6% | 34.8% |
| 設備投資強度設備投資 / 売上 | 4.9% | 20.5% |
| キャッシュ転換率営業CF / 純利益 | — | 5.02× |
| 直近12ヶ月FCF直近4四半期 | $-1.3M | $277.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $27.7M | $139.5M | ||
| Q3 25 | $12.4M | $75.9M | ||
| Q2 25 | $11.6M | $124.2M | ||
| Q1 25 | $-18.4M | $54.7M | ||
| Q4 24 | $23.7M | $130.2M | ||
| Q3 24 | $11.7M | $48.5M | ||
| Q2 24 | $9.0M | $96.7M | ||
| Q1 24 | $-18.6M | $65.9M |
| Q4 25 | $16.8M | $87.7M | ||
| Q3 25 | $2.5M | $51.9M | ||
| Q2 25 | $4.5M | $101.1M | ||
| Q1 25 | $-25.1M | $36.3M | ||
| Q4 24 | $15.2M | $101.2M | ||
| Q3 24 | $6.3M | $19.8M | ||
| Q2 24 | $-360.0K | $48.2M | ||
| Q1 24 | $-29.1M | $-32.7M |
| Q4 25 | 7.6% | 34.8% | ||
| Q3 25 | 1.2% | 20.7% | ||
| Q2 25 | 2.2% | 40.4% | ||
| Q1 25 | -13.0% | 14.8% | ||
| Q4 24 | 7.0% | 41.1% | ||
| Q3 24 | 3.2% | 8.2% | ||
| Q2 24 | -0.2% | 20.5% | ||
| Q1 24 | -15.4% | -14.3% |
| Q4 25 | 4.9% | 20.5% | ||
| Q3 25 | 4.8% | 9.6% | ||
| Q2 25 | 3.5% | 9.3% | ||
| Q1 25 | 3.5% | 7.5% | ||
| Q4 24 | 4.0% | 11.8% | ||
| Q3 24 | 2.7% | 12.0% | ||
| Q2 24 | 4.7% | 20.6% | ||
| Q1 24 | 5.6% | 43.0% |
| Q4 25 | — | 5.02× | ||
| Q3 25 | — | 2.20× | ||
| Q2 25 | — | 4.35× | ||
| Q1 25 | — | 2.66× | ||
| Q4 24 | — | 5.12× | ||
| Q3 24 | — | 2.51× | ||
| Q2 24 | — | 3.10× | ||
| Q1 24 | — | 2.80× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
USAC
| Revenue From Contract Operations Excluding Revenue From Related Party | $231.7M | 92% |
| Entities Affiliated With Energy Transfer LP | $16.6M | 7% |
| Transferred At Point In Time | $5.4M | 2% |
